Treatment
 |
Download and review key data selected by Daniel Shouval, MD on clinical HBV data that was presented at the 2008 EASL meeting in Milan. Use the slides in your own presentations!
File Format: Microsoft PowerPoint (.ppt) | File Size: 796 KB
Date Posted: 5/9/2008
|
|
Randomized trial suggests a significant reduction in HBsAg level during peginterferon-based therapy is the best predictor of HBsAg clearance during 3 years of follow-up
Date Posted: 4/30/2008
|
|
Results of Japanese studies (ETV-047, ETV-053, ETV-060) reveal that treatment with entecavir is both safe and effective for up to 3 years, and a higher barrier to resistance is maintained in treatment-naive chronic hepatitis B patients
Date Posted: 4/29/2008
|
|
Analysis of chronic hepatitis B patients with lamivudine resistance from Chinese studies (ETV-056 and ETV-050) reveals increasing rates of HBV DNA negativity and HBeAg outcomes following 3 years of treatment
Date Posted: 4/28/2008
|
|
Retrospective analysis of major telbivudine trials suggests that 6 months of consolidation therapy effective at maintaining HBeAg seroconversion in patients treated with either lamivudine or telbivudine
Date Posted: 4/28/2008
|
|
In this double-blind, randomized trial, 2 tenofovir-containing regimens were shown to significantly decrease HBV DNA at 48 weeks in patients who were previously unresponsive to adefovir therapy
Date Posted: 4/28/2008
|
|
Tenofovir treatment associated with virologic suppression in treatment-experienced patients, but efficacy was affected by previous treatment with adefovir or presence of adefovir resistance
Date Posted: 4/28/2008
|
|
Through a mean 57 months of follow-up, the strategy of combination therapy with adefovir and lamivudine continues to be effective for patients with lamivudine resistance
Date Posted: 4/27/2008
|
|
Study 102 illustrated that viral suppression as a result of tenofovir therapy is sustained over 72 weeks without the emergence of resistance
Date Posted: 4/27/2008
|
|
Continuous treatment with tenofovir through Week 72 in HBeAg-positive patients resulted in persistent HBV DNA suppression and additional cases of HBsAg loss whereas switching from adefovir to tenofovir resulted in potent reductions of HBV DNA
Date Posted: 4/27/2008
|
|
Featured Content
2008 Independent Conference Report on Hepatitis B and C Virus Resistance to Antiviral Therapies.
Review new data and Expert Highlights from the 2008 hepatitis meeting.
Review a module and Interactive Case Challenge and use the new HBV DNA monitoring tool.
|
|